rupiya.io
⠋Loading...
0%
❯ Analyzing price movements...
Solara Active Pharma Sciences Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Solara Active Pharma Sciences Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | ₹521 Cr | ₹1,387 Cr | ₹1,322 Cr | |||||
| Expenses | ₹464 Cr | ₹1,174 Cr | ₹1,062 Cr | |||||
| Operating Profit | ₹57 Cr | ₹213 Cr | ₹260 Cr | |||||
| OPM % | 11.0% | 15.0% | 20.0% | |||||
| Other Income | ₹2 Cr | ₹12 Cr | ₹27 Cr | |||||
| Depreciation | ₹34 Cr | ₹83 Cr | ₹94 Cr | |||||
| Interest | ₹25 Cr | ₹82 Cr | ₹78 Cr | |||||
| Profit Before Tax | ₹0 Cr | ₹60 Cr | ₹115 Cr | |||||
| Tax | ₹0 Cr | ₹60 Cr | ₹115 Cr | |||||
| Net Profit | ₹0 Cr | ₹59 Cr | ₹115 Cr | |||||
| EPS (₹) | 0.0 | 17.3 | 32.0 | |||||
| Dividend Payout % | 0% | 22% | 5% |
Register free to see 5 more years.
| Quarter | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹381 Cr | ₹352 Cr | ₹425 Cr | ₹212 Cr | ||||||||
| Expenses | ₹332 Cr | ₹333 Cr | ₹388 Cr | ₹374 Cr | ||||||||
| Operating Profit | ₹49 Cr | ₹19 Cr | ₹38 Cr | ₹-162 Cr | ||||||||
| OPM % | 12.8% | 5.4% | 8.9% | -76.3% | ||||||||
| Depreciation | ₹26 Cr | ₹26 Cr | ₹26 Cr | ₹26 Cr | ||||||||
| Interest | ₹22 Cr | ₹25 Cr | ₹24 Cr | ₹25 Cr | ||||||||
| Net Profit | ₹4 Cr | ₹-19 Cr | ₹-17 Cr | ₹-275 Cr | ||||||||
| EPS (₹) | 0.8 | -4.1 | -3.6 | -57.4 |
Register free to see 8 more quarters.
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹25 Cr | ₹26 Cr | ₹27 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹739 Cr | ₹930 Cr | ₹1,059 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹633 Cr | ₹538 Cr | ₹722 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹425 Cr | ₹466 Cr | ₹346 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹1,821 Cr | ₹1,960 Cr | ₹2,153 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹1,086 Cr | ₹1,218 Cr | ₹1,397 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹1 Cr | ₹0 Cr | ₹0 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹663 Cr | ₹701 Cr | ₹716 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹1,821 Cr | ₹1,960 Cr | ₹2,153 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 5 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2019 | ₹49 Cr | ₹-85 Cr | ₹68 Cr | — |
| Mar 2020 | ₹166 Cr | ₹-113 Cr | ₹-23 Cr | — |
| Mar 2021 | ₹242 Cr | ₹-359 Cr | ₹97 Cr | — |
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 | ||||
| Mar 2026 |
Register free to see 5 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +4.58% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +5.05% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -8.88% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +11.69% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +5.77% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.